Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
ASTRAZENECA is spinning off six early-stage experimental drugs into a new US$250 million stand-alone biotech company focused on severe autoimmune diseases.
The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest